Hope emerging in the locally advanced cervical cancer landscape
Mené sur 1 060 patientes atteintes d'un cancer du col de l'utérus de stade localement avancé, cet essai international randomisé de phase III évalue l'efficacité, du point de vue de la survie sans progression, et la sécurité d'un ajout de pembrolizumab à une chimioradiothérapie
Locally advanced cervical cancer accounts for around 40% of all cervical cancers. Cisplatin-based chemoradiotherapy followed by brachytherapy has been the recommended treatment for over 20 years. Although conformal radiotherapy techniques have improved local control and reduced toxicity, distant metastases are still responsible for most recurrences. Despite trials testing various therapeutic strategies, nothing has been proven to improve survival.